Skip to main content
Midas Edge

Xilio Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

XLO$8.53-5.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

CONSOLIDATED STATEMENTS OF

STOCKHOLDERS’ EQUITY

(In thousands, except share data)

​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Amount · Capital · Deficit · Equity
Balance at December 31, 2021​27,358,375​$3​$346,312​$(160,886)​$185,429
Vesting of restricted common stock64,415​—​—​—​—
Exercise of stock options2,657​—​16​—​16
Stock-based compensation expense—​—​8,424​—​8,424
Net loss—​—​—​(88,222)​(88,222)
Balance at December 31, 202227,425,447​$3​$354,752​$(249,108)​$105,647
Issuance of common stock under employee stock purchase plan​140,192​​—​​194​​—​​194
Vesting of restricted common stock39,250​—​—​—​—
Exercise of stock options2,757​—​8​—​8
Stock-based compensation expense—​—​7,382​—​7,382
Net loss—​—​—​(76,404)​(76,404)
Balance at December 31, 202327,607,646​$3​$362,336​$(325,512)​$36,827

XILIO THERAPEUTICS, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.